Unlock News Summary by Subscribing to iPick.ai Premium!
Ask anything related to PCVX. [ FAQ on what and how to ask] For non-PCVX questions, click the logo in the upper-right corner to return to the main page and ask there.
Unlock YouTube Video by Subscribing to iPick.ai Premium!
No verified billionaire connection found.
Address: 825 Industrial Road, Suite 300, San Carlos, CA, United States, 94070
Employees: 507
Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV for the prevention of IPD in adults and children; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting the keystone pathogen responsible for periodontitis; VAX-GI, a novel preclinical vaccine candidate for the treatment of dysentery and shigellosis, which is caused by Shigella bacteria; and VAX-XL, a third-generation pneumococcal conjugate vaccine. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
Co-Founder, CEO & Director
President & CFO
Executive VP, Chief Scientific Officer & COO
Chief Technical Operations Officer
Co-Founder & VP of Research
Senior VP of Finance & Chief Accounting Officer
Executive Director of Investor Relations
Chief Legal Officer, Chief Compliance Officer & Corporate Secretary
Chief People Officer
Senior Vice President of Corporate Affairs
My Watchlist
